{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:18:19Z","timestamp":1794629899703,"version":"4.9.1"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"abstract":"<jats:p>\n                    BICtegravir Single Tablet Regimen is a multiregional, observational cohort study assessing the effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in treatment-na\u00efve (TN) and treatment-experienced (TE) people with HIV. We present 24-month data for the BICtegravir Single Tablet Regimen Asia cohort. Between December 2020 and March 2024, prospective and retrospective data were collected from TN and TE people with HIV receiving B\/F\/TAF in routine clinical care in the Republic of Korea, Singapore, and Taiwan. Endpoints at month 24 included effectiveness (HIV-1 RNA\u2005&lt;50 copies\/mL; missing\u2005=\u2005excluded and discontinuation\u2005=\u2005failure analyses), immunological endpoints (CD4 cell count and CD4\/CD8 ratio), persistence, safety, and patient-reported outcomes (prospective cohort). Overall, 334 participants (252 prospective, 82 retrospective; 66 TN, 268 TE) were included in the analysis population. Most were male (97% TN, 93% TE) with \u22651 comorbidity (56% TN, 67% TE). At month 24, HIV-1 RNA was &lt;50 copies\/mL in 91% (50\/55) of TN and 97% (225\/331) of TE participants (missing\u2005=\u2005excluded analysis). Median (quartile [Q]1, Q3) CD4 count increased by +260 (155, 386;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) cells\/\u03bcL in TN and +40 (\u221265, 150;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.008) cells\/\u03bcL in TE participants. Median (Q1, Q3) CD4\/CD8 ratio increased by +0.38 (0.21, 0.48;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) in TN and +0.08 (0.00, 0.19;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) in TE participants. Patient-reported outcomes indicated an improvement in mental health and a decrease in the number of bothersome symptoms in TN participants. Persistence at month 24 was high, with 98% (60\/61) of TN and 97% (251\/260) of TE participants remaining on B\/F\/TAF. Drug-related adverse events occurred in 9% (6\/66) of TN and 8% (22\/268) of TE participants, leading to B\/F\/TAF discontinuation in &lt;1% (3\/334) of participants, all of whom were TE. B\/F\/TAF demonstrated high levels of effectiveness, persistence, and tolerability over 24 months in people with HIV in Asia.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047358","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T17:01:13Z","timestamp":1769965273000},"page":"e47358","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV in Asia: 24-Month findings from the observational BICSTaR study"],"prefix":"10.1097","volume":"105","author":[{"given":"Chia-Jui","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan"},{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon-Sook","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Yong","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaw Yee","family":"Choy","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, National Centre for Infectious Diseases, Singapore, Singapore"},{"name":"Tan Tock Seng Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Liang","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chin","family":"Tsai","sequence":"additional","affiliation":[{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"},{"name":"Section of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Ryu","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Gilead Sciences, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Harrison","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Chang","sequence":"additional","affiliation":[{"name":"Medical Affairs, Gilead Sciences, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billy","family":"Mo","sequence":"additional","affiliation":[{"name":"Medical Affairs, Gilead Sciences, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pusan National University School of Medicine and Pusan National University Hospital, Busan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7345-0836","authenticated-orcid":false,"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan"},{"name":"Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan"},{"name":"Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-20260519","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3851\/IMP3041","article-title":"Improved survival in HIV treatment programmes in Asia.","volume":"21","author":"De La Mata","year":"2016","journal-title":"Antivir Ther"},{"key":"R4-20260519","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/hiv.12188","article-title":"HIV and aging: insights from the Asia Pacific HIV observational database (APHOD).","volume":"16","author":"Han","year":"2015","journal-title":"HIV Med"},{"key":"R5-20260519","doi-asserted-by":"crossref","first-page":"e25219","DOI":"10.1002\/jia2.25219","article-title":"Trends in mortality among ART-treated HIV-infected adults in the Asia-Pacific region between 1999 and 2017: results from the TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database (AHOD) of IeDEA Asia-Pacific.","volume":"22","author":"Jung","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"R6-20260519","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1097\/QAI.0000000000001258","article-title":"HIV and aging: demographic change in the Asia-Pacific region.","volume":"74","author":"Puhr","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R7-20260519","first-page":"27","article-title":"The management of polypharmacy in people living with HIV.","volume":"25","author":"Marin","year":"2023","journal-title":"AIDS Rev"},{"key":"R8-20260519","doi-asserted-by":"crossref","first-page":"ofz531","DOI":"10.1093\/ofid\/ofz531","article-title":"Polypharmacy, drug-drug interactions, and inappropriate drugs: new challenges in the aging population with HIV.","volume":"6","author":"Courlet","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"R9-20260519","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society\u2013USA panel.","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"R10-20260519","doi-asserted-by":"crossref","first-page":"e26002","DOI":"10.1002\/jia2.26002","article-title":"Providing differentiated service delivery to the ageing population of people living with HIV.","volume":"25","author":"Godfrey","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"R11-20260519","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3851\/IMP3293","article-title":"Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study.","volume":"24","author":"Halloran","year":"2019","journal-title":"Antivir Ther"},{"key":"R12-20260519","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3390\/ijerph19042359","article-title":"Aging with HIV: increased risk of HIV comorbidities in older adults.","volume":"19","author":"Roomaney","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R14-20260519","doi-asserted-by":"crossref","first-page":"106898","DOI":"10.1016\/j.phrs.2023.106898","article-title":"Pillars of long-term antiretroviral therapy success.","volume":"196","author":"Taramasso","year":"2023","journal-title":"Pharmacol Res"},{"key":"R16-20260519","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/hiv.13460","article-title":"Long-term success for people living with HIV: a framework to guide practice.","volume":"24","author":"Lazarus","year":"2023","journal-title":"HIV Med"},{"key":"R17-20260519","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","article-title":"Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries.","volume":"17","author":"Cohen","year":"2020","journal-title":"AIDS Res Ther"},{"key":"R18-20260519","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/QAI.0000000000002137","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B\/F\/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority Trial.","volume":"82","author":"Kityo","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R19-20260519","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"R20-20260519","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"key":"R21-20260519","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus.","volume":"73","author":"Sax","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R22-20260519","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","article-title":"Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"R23-20260519","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"R24-20260519","doi-asserted-by":"crossref","first-page":"107164","DOI":"10.1016\/j.ijantimicag.2024.107164","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as first-line treatment in naive HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.","volume":"63","author":"Hidalgo-Tenorio","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"R25-20260519","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/hiv.13319","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people \u226565 years of age.","volume":"24","author":"Maggiolo","year":"2023","journal-title":"HIV Med"},{"key":"R26-20260519","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/hiv.13386","article-title":"Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: a pooled analysis from three international phase III randomized trials.","volume":"24","author":"Avihingsanon","year":"2022","journal-title":"HIV Med"},{"key":"R27-20260519","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3947\/ic.2021.0305","article-title":"Summary of 2021 clinical guidelines for the diagnosis and treatment of HIV\/AIDS in HIV-infected Koreans.","volume":"53","year":"2021","journal-title":"Infect Chemother"},{"key":"R28-20260519","doi-asserted-by":"crossref","first-page":"259","DOI":"10.11622\/smedj.2021174","article-title":"Recommendations for the use of antiretroviral therapy in adults living with human immunodeficiency virus in Singapore.","volume":"65","author":"Choy","year":"2024","journal-title":"Singapore Med J"},{"key":"R30-20260519","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jac\/dkab481","article-title":"Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre.","volume":"77","author":"Ambrosioni","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R31-20260519","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.2147\/IDR.S331647","article-title":"Outcomes after switching to BIC\/FTC\/TAF in patients with virological failure to protease inhibitors or non-nucleoside reverse transcriptase inhibitors: a real-world cohort study.","volume":"14","author":"Chang","year":"2021","journal-title":"Infect Drug Resist"},{"key":"R32-20260519","doi-asserted-by":"crossref","first-page":"e27330","DOI":"10.1097\/MD.0000000000027330","article-title":"Real-world efficacy and safety of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in older people living with HIV.","volume":"100","author":"Rolle","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"R33-20260519","doi-asserted-by":"crossref","first-page":"106631","DOI":"10.1016\/j.ijantimicag.2022.106631","article-title":"Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.","volume":"60","author":"Chen","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"R34-20260519","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40121-022-00734-5","article-title":"Comparison of virological efficacy of DTG\/ABC\/3TG and B\/F\/TAF regimens and discontinuation patterns in persons living with advanced HIV in the era of rapid ART: a retrospective multicenter cohort study.","volume":"12","author":"Lee","year":"2023","journal-title":"Infect Dis Ther"},{"key":"R35-20260519","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2022.11.012","article-title":"Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N\/R mutation.","volume":"126","author":"Tsai","year":"2023","journal-title":"Int J Infect Dis"},{"key":"R36-20260519","first-page":"e26370","article-title":"P301 Dolutegravir\/lamivudine versus bictegravir\/emtricitabine\/tenofovir alafenamide fumarate: real-world assessment of weight gain in people living with HIV of Asian origin (DRAGON study).","volume":"27","author":"Chen","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"R37-20260519","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jgar.2023.10.012","article-title":"Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir\/emtricitabine\/tenofovir alafenamide.","volume":"36","author":"Hsu","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"R38-20260519","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/jac\/dkae086","article-title":"Trends of pre-treatment drug resistance in antiretroviral-naive people with HIV-1 in the era of second-generation integrase strand-transfer inhibitors in Taiwan.","volume":"79","author":"Chen","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"R39-20260519","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/hiv.13593","article-title":"Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV: real-world insights from BICSTaR cohorts.","volume":"25","author":"Esser","year":"2024","journal-title":"HIV Med"},{"key":"R40-20260519","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jmii.2024.07.003","article-title":"Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in treatment-naive and treatment-experienced people with HIV: findings from the Asia cohort of the BICSTaR study.","volume":"57","author":"Tseng","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"key":"R41-20260519","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/09564624241308372","article-title":"Effectiveness, safety, and patient-reported outcomes of bictegravir\/emtricitabine\/tenofovir alafenamide in routine clinical care in Italy: 12-month results from the BICSTaR cohort.","volume":"36","author":"Antinori","year":"2025","journal-title":"Int J STD AIDS"},{"key":"R42-20260519","doi-asserted-by":"crossref","first-page":"100685","DOI":"10.1016\/j.ijregi.2025.100685","article-title":"Real-world effectiveness, safety, and health-related quality of life in people living with HIV receiving bictegravir\/emtricitabine\/tenofovir alafenamide\u201312-month results of the BICSTaR French cohort.","volume":"16","author":"Hocqueloux","year":"2025","journal-title":"IJID Reg"},{"key":"R43-20260519","doi-asserted-by":"crossref","first-page":"e37785","DOI":"10.1097\/MD.0000000000037785","article-title":"Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV from the Canadian cohort of the observational BICSTaR study.","volume":"103","author":"Wong","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"R44-20260519","doi-asserted-by":"crossref","first-page":"e0313338","DOI":"10.1371\/journal.pone.0313338","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in treatment-na\u00efve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort.","volume":"20","author":"Yokomaku","year":"2025","journal-title":"PLoS One"},{"key":"R45-20260519","doi-asserted-by":"crossref","first-page":"2456890","DOI":"10.1080\/25787489.2025.2456890","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort.","volume":"26","author":"Trottier","year":"2025","journal-title":"HIV Res Clin Pract"},{"key":"R49-20260519","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijid.2021.07.030","article-title":"Long-term weight gain after initiating combination antiretroviral therapy in treatment-naive Asian people living with human immunodeficiency virus.","volume":"110","author":"Ando","year":"2021","journal-title":"Int J Infect Dis"},{"key":"R50-20260519","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1097\/QAD.0000000000003950","article-title":"Choice of antiretroviral therapy has low impact on weight gain.","volume":"38","author":"Drechsler","year":"2024","journal-title":"AIDS"},{"key":"R51-20260519","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fendo.2018.00705","article-title":"The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality.","volume":"9","author":"Kumar","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R53-20260519","doi-asserted-by":"crossref","first-page":"e34733","DOI":"10.1016\/j.heliyon.2024.e34733","article-title":"Weight gain, new-onset overweight or obesity, and their influencing factors during the social distancing era of the COVID-19 pandemic.","volume":"10","author":"Lee","year":"2024","journal-title":"Heliyon"},{"key":"R54-20260519","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/cid\/ciab444","article-title":"Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials.","volume":"73","author":"Erlandson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R55-20260519","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European atherosclerosis society consensus panel.","volume":"41","author":"Boren","year":"2020","journal-title":"Eur Heart J"},{"key":"R56-20260519","first-page":"221","article-title":"Chinese guidelines for lipid management (2023).","volume":"51","year":"2023","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047358","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:05:05Z","timestamp":1779195905000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047358","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"2025-09-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}